Advanced search
Publication Cover
Epigenomics Volume 4, 2012 - Issue 2
Submit an article Journal homepage
337
Views
2
CrossRef citations to date
0
Altmetric
Review

Promoter CpG Island Methylation Markers in Colorectal Cancer: The Road Ahead

Muriel XG Draht1 Department of Pathology, GROW-School for Oncology & Developmental Biology, Maastricht University Medical Center, Maastricht, The NetherlandsView further author information
,
Robert R Riedl1 Department of Pathology, GROW-School for Oncology & Developmental Biology, Maastricht University Medical Center, Maastricht, The NetherlandsView further author information
,
Hanneke Niessen1 Department of Pathology, GROW-School for Oncology & Developmental Biology, Maastricht University Medical Center, Maastricht, The NetherlandsView further author information
,
Beatriz Carvalho2 Department of Pathology, VU University Medical Center, Amsterdam, The NetherlandsView further author information
,
Gerrit A Meijer2 Department of Pathology, VU University Medical Center, Amsterdam, The NetherlandsView further author information
,
James G Herman3 The Johns Hopkins University School of Medicine, Baltimore, MD, USAView further author information
,
Manon van Engeland1 Department of Pathology, GROW-School for Oncology & Developmental Biology, Maastricht University Medical Center, Maastricht, The NetherlandsView further author information
,
Veerle Melotte1 Department of Pathology, GROW-School for Oncology & Developmental Biology, Maastricht University Medical Center, Maastricht, The NetherlandsCorrespondence[email protected]
View further author information
&
Kim M Smits1 Department of Pathology, GROW-School for Oncology & Developmental Biology, Maastricht University Medical Center, Maastricht, The NetherlandsView further author information
 show all
Pages 179-194 | Published online: 27 Mar 2012

References

  • Jemal A , SiegelR, WardE, HaoY, XuJ, ThunMJ. Cancer statistics, 2009. CA Cancer J. Clin.59(4) , 225–249 (2009).
  • Ferlay J , ShinHR, BrayF, FormanD, MathersC, ParkinDM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer127(12) , 2893–2917 (2010).
  • Jemal A , BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J. Clin.61(2) , 69–90 (2011).
  • Morris EJ , MaughanNJ, FormanD, QuirkeP. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut56(10) , 1419–1425 (2007).
  • Jass JR . Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology50(1) , 113–130 (2007).
  • Hughes LA , Khalid-De Bakker CA, Smits KM et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim. Biophys. Acta1825(1) , 77–85 (2012).
  • George B , KopetzS. Predictive and prognostic markers in colorectal cancer. Curr. Oncol. Rep.13(3) , 206–215 (2011).
  • Mutch MG . Molecular profiling and risk stratification of adenocarcinoma of the colon. J. Surg. Oncol.96(8) , 693–703 (2007).
  • Walther A , JohnstoneE, SwantonC, MidgleyR, TomlinsonI, KerrD. Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer9(7) , 489–499 (2009).
  • Kondo Y , IssaJP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev.23(1–2) , 29–39 (2004).
  • Chan TA , GlocknerS, YiJM et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 5(5) , e114 (2008).
  • Smits KM , Cleven a H, Weijenberg MP et al. Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. Pharmacogenomics9(12) , 1903–1916 (2008).
  • Bock C . Epigenetic biomarker development. Epigenomics1(1) , 99–110 (2009).
  • Esteller M , FragaMF, GuoM et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 10(26) , 3001–3007 (2001).
  • Herman JG , BaylinSB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med.349(21) , 2042–2054 (2003).
  • Van Engeland M , DerksS, SmitsKM, MeijerGA, HermanJG. Colorectal cancer epigenetics: complex simplicity. J. Clin. Oncol.29(10) , 1382–1391 (2011).
  • Takai D , JonesPA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl Acad. Sci. USA99(6) , 3740–3745 (2002).
  • Vucic EA , BrownCJ, LamWL. Epigenetics of cancer progression. Pharmacogenomics9(2) , 215–234 (2008).
  • Okano M , BellDW, HaberDA, LiE. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell99(3) , 247–257 (1999).
  • Esteller M . Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet.16(Spec No 1) , R50–R59 (2007).
  • Jost JP , BruhatA. The formation of DNA methylation patterns and the silencing of genes. Prog. Nucleic Acid Res. Mol. Biol.57 , 217–248 (1997).
  • Kim H , ParkJ, JungY et al. DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells. Int. J. Oncol. 36(6) , 1563–1572 (2010).
  • Turker MS , BestorTH. Formation of methylation patterns in the mammalian genome. Mutat. Res.386(2) , 119–130 (1997).
  • Merlo A , HermanJG, MaoL et al. 5´ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1(7) , 686–692 (1995).
  • Baylin SB , HermanJG, GraffJR, VertinoPM, IssaJP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res.72 , 141–196 (1998).
  • Bird A . The essentials of DNA methylation. Cell70(1) , 5–8 (1992).
  • Costello JF , FruhwaldMC, SmiragliaDJ et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24(2) , 132–138 (2000).
  • Esteller M . CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene21(35) , 5427–5440 (2002).
  • Irizarry RA , Ladd-AcostaC, WenB et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41(2) , 178–186 (2009).
  • Doi A , ParkIH, WenB et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41(12) , 1350–1353 (2009).
  • Lopez-Serra L , EstellerM. Proteins that bind methylated DNA and human cancer: reading the wrong words. Br. J. Cancer98(12) , 1881–1885 (2008).
  • Kuroda A , RauchTA, TodorovI et al. Insulin gene expression is regulated by DNA methylation. PLoS ONE 4(9) , e6953 (2009).
  • Hoque MO , KimMS, OstrowKL et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res. 68(8) , 2661–2670 (2008).
  • Momparler RL . Cancer epigenetics. Oncogene22(42) , 6479–6483 (2003).
  • Sharma S , KellyTK, JonesPA. Epigenetics in cancer. Carcinogenesis31(1) , 27–36 (2010).
  • Issa JP . CpG island methylator phenotype in cancer. Nat. Rev. Cancer4(12) , 988–993 (2004).
  • Toyota M , AhujaN, Ohe-ToyotaM, HermanJG, BaylinSB, IssaJP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA96(15) , 8681–8686 (1999).
  • Tanaka N , HuttenhowerC, NoshoK et al. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am. J. Pathol. 177(6) , 2731–2740 (2010).
  • Weisenberger DJ , SiegmundKD, CampanM et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38(7) , 787–793 (2006).
  • Park SJ , RashidA, LeeJH, KimSG, HamiltonSR, WuTT. Frequent CpG island methylation in serrated adenomas of the colorectum. Am. J. Pathol.162(3) , 815–822 (2003).
  • Ogino S , CantorM, KawasakiT et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55(7) , 1000–1006 (2006).
  • Shen L , ToyotaM, KondoY et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA 104(47) , 18654–18659 (2007).
  • Samowitz WS , AlbertsenH, HerrickJ et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129(3) , 837–845 (2005).
  • Toyota M , Ohe-ToyotaM, AhujaN, IssaJP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc. Natl Acad. Sci. USA97(2) , 710–715 (2000).
  • Tainsky MA . Cancer biomarker discovery: speed-bumps and tire shredders. Cancer Biomark.6(5–6) , 225–227 (2010).
  • Issaq HJ , WaybrightTJ, VeenstraTD. Cancer biomarker discovery: Opportunities and pitfalls in analytical methods. Electrophoresis32(9) , 967–975 (2011).
  • Crea F , NobiliS, PaolicchiE et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist. Updat. 14(6) , 280–296 (2011).
  • Naylor S . Biomarkers: current perspectives and future prospects. Expert Rev. Mol. Diagn.3(5) , 525–529 (2003).
  • Perera FP , WeinsteinIB. Molecular epidemiology: recent advances and future directions. Carcinogenesis21(3) , 517–524 (2000).
  • Vineis P , PereraF. Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidemiol. Biomarkers Prev.16(10) , 1954–1965 (2007).
  • Levin B , LiebermanDA, McfarlandB et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5) , 1570–1595 (2008).
  • Gatto NM , FruchtH, SundararajanV, JacobsonJS, GrannVR, NeugutAI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J. Natl Cancer Inst.95(3) , 230–236 (2003).
  • Frazier a L , ColditzGA, FuchsCS, KuntzKM. Cost–effectiveness of screening for colorectal cancer in the general population. JAMA284(15) , 1954–1961 (2000).
  • Imperiale TF , RansohoffDF, ItzkowitzSH, TurnbullBA, RossME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med.351(26) , 2704–2714 (2004).
  • Bosch LJ , CarvalhoB, FijnemanRJ et al. Molecular tests for colorectal cancer screening. Clin. Colorectal Cancer 10(1) , 8–23 (2011).
  • Chen WD , HanZJ, SkoletskyJ et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl Cancer Inst. 97(15) , 1124–1132 (2005).
  • Itzkowitz S , BrandR, JandorfL et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am. J. Gastroenterol. 103(11) , 2862–2870 (2008).
  • Itzkowitz SH , JandorfL, BrandR et al. Improved fecal DNA test for colorectal cancer screening. Clin. Gastroenterol. Hepatol. 5(1) , 111–117 (2007).
  • Li M , ChenWD, PapadopoulosN et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 27(9) , 858–863 (2009).
  • Ahlquist DA , SkoletskyJE, BoyntonKA et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119(5) , 1219–1227 (2000).
  • Ned RM , MelilloS, MarroneM. Fecal DNA testing for colorectal cancer screening: the ColoSure™ test. PLoS Curr.3 , RRN1220 (2011).
  • Huang Z , LiL, WangJ. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig. Dis. Sci.52(9) , 2287–2291 (2007).
  • Wang DR , TangD. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J. Gastroenterol.14(4) , 524–531 (2008).
  • Oberwalder M , ZittM, WontnerC et al. SFRP2 methylation in fecal DNA – a marker for colorectal polyps. Int. J. Colorectal Dis. 23(1) , 15–19 (2008).
  • Nagasaka T , TanakaN, CullingsHM et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J. Natl Cancer Inst. 101(18) , 1244–1258 (2009).
  • Zhang W , BauerM, CronerRS et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis. Colon Rectum 50(10) , 1618–1626; discussion 1626–1617 (2007).
  • Lenhard K , BommerGT, AsutayS et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin. Gastroenterol. Hepatol. 3(2) , 142–149 (2005).
  • Petko Z , GhiassiM, ShuberA et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin. Cancer Res. 11(3) , 1203–1209 (2005).
  • Leung WK , ToKF, ManEP et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am. J. Gastroenterol. 102(5) , 1070–1076 (2007).
  • Melotte V , LentjesMH, Van Den Bosch SM et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl Cancer Inst.101(13) , 916–927 (2009).
  • Hellebrekers DM , LentjesMH, Van Den Bosch SM et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin. Cancer Res.15(12) , 3990–3997 (2009).
  • Glöckner SC , DhirM, YiJM et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69(11) , 4691–4699 (2009).
  • Kim MS , LouwagieJ, CarvalhoB et al. Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS ONE 4(8) , e6555 (2009).
  • Bosch LJ , OortFA, NeerincxM et al. DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT. Cancer Prev. Res. (Phila.) 5(3) , 464–472 (2012).
  • Ahlquist DA , ZouH, DomanicoM et al. Next-generation stool DNA test accurately detects colorectal cancer or large adenomas. Gastroenterology 142(2) , 248–256 (2011).
  • Leung WK , ToKF, ManEP et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am. J. Gastroenterol. 100(10) , 2274–2279 (2005).
  • Ebert MP , ModelF, MooneyS et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology 131(5) , 1418–1430 (2006).
  • Lofton-Day C , ModelF, DevosT et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54(2) , 414–423 (2008).
  • Herbst A , RahmigK, StieberP et al. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am. J. Gastroenterol. 106(6) , 1110–1118 (2011).
  • Devos T , TetznerR, ModelF et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 55(7) , 1337–1346 (2009).
  • Payne SR . From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood. Epigenomics2(4) , 575–585 (2010).
  • Tanzer M , BalluffB, DistlerJ et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS ONE 5(2) , e9061 (2010).
  • Warren JD , XiongW, Bunker a M et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med.9(1) , 133 (2011).
  • Tang D , LiuJ, WangDR, YuHF, LiYK, ZhangJQ. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin. Invest. Med.34(2) , E88–E95 (2011).
  • Ahlquist DA , TaylorWR, MahoneyDW et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin. Gastroenterol. Hepatol. 10(3) , 272–277 (2012).
  • Deschoolmeester V , BaayM, SpecenierP, LardonF, VermorkenJB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist15(7) , 699–731 (2010).
  • Graziano F , CascinuS. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes‘ B colorectal cancer patients: how much evidence is enough? Ann. Oncol.14(7) , 1026–1038 (2003).
  • Klump B , NehlsO, OkechT et al. Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int. J. Colorectal Dis. 19(1) , 23–42 (2004).
  • Belt EJ , Van Stijn MF, Bril H et al. Lymph node negative colorectal cancers with isolated tumor deposits should be classified and treated as stage III. Ann. Surg. Oncol.17(12) , 3203–3211 (2010).
  • George S , PrimroseJ, TalbotR et al. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br. J. Cancer 95(7) , 841–847 (2006).
  • Nosho K , BabaY, TanakaN et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol. 222(4) , 350–366 (2010).
  • Prall F , NizzeH, BartenM. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology47(1) , 17–24 (2005).
  • Pritchard CC , GradyWM. Colorectal cancer molecular biology moves into clinical practice. Gut60(1) , 116–129 (2011).
  • Fretwell VL , AngCW, TweedleEM, RooneyPS. The impact of lymph node yield on Duke‘s B and C colorectal cancer survival. Colorectal Dis.12(10) , 995–1000 (2010).
  • Chau I , AllenMJ, CunninghamD et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J. Clin. Oncol. 22(8) , 1420–1429 (2004).
  • Oussoultzoglou E , RossoE, FuchshuberP et al. Perioperative carcinoembryonic antigen measurements to predict curability after liver resection for colorectal metastases: a prospective study. Arch. Surg. 143(12) , 1150–1158; discussion 1158–1159 (2008).
  • Tan E , GouvasN, NichollsRJ, ZiprinP, XynosE, TekkisPP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg. Oncol.18(1) , 15–24 (2009).
  • Kelley RK , Venook a P. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin. Colorectal Cancer10(2) , 73–80 (2011).
  • Umetani N , TakeuchiH, FujimotoA, ShinozakiM, Bilchik a J, Hoon DS. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin. Cancer Res.10(22) , 7475–7483 (2004).
  • Tanaka M , ChangP, LiY et al. Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin. Cancer Res. 17(13) , 4531–4540 (2011).
  • Krtolica K , KrajnovicM, Usaj-KnezevicS, BabicD, JovanovicD, DimitrijevicB. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J. Gastroenterol.13(8) , 1187–1194 (2007).
  • Whitehall VL , WalshMD, YoungJ, LeggettBA, JassJR. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res.61(3) , 827–830 (2001).
  • Xu XL , YuJ, ZhangHY et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J. Gastroenterol. 10(23) , 3441–3454 (2004).
  • Ogino S , NoshoK, KirknerGJ et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58(1) , 90–96 (2009).
  • Shima K , MorikawaT, BabaY et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control 22(2) , 301–309 (2011).
  • Kohonen-Corish MR , DanielJJ, ChanC et al. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J. Clin. Oncol. 23(10) , 2318–2324 (2005).
  • Mokarram P , KumarK, BrimH et al. Distinct high-profile methylated genes in colorectal cancer. PLoS ONE 4(9) , e7012 (2009).
  • Yi JM , DhirM, Van Neste L et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin. Cancer Res.17(6) , 1535–1545 (2011).
  • Ahn JB , ChungWB, MaedaO et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117(9) , 1847–1854 (2011).
  • Ward RL , CheongK, KuSL, MeagherA, O‘connorT, HawkinsNJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J. Clin. Oncol.21(20) , 3729–3736 (2003).
  • Barault L , Charon-BarraC, JoosteV et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 68(20) , 8541–8546 (2008).
  • Saltz LB , NiedzwieckiD, HollisD et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 25(23) , 3456–3461 (2007).
  • Edwards MS , ChaddaSD, ZhaoZ, BarberBL, SykesDP. A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis.14(2) , e31–e47 (2012).
  • Goldberg RM . Therapy for metastatic colorectal cancer. Oncologist11(9) , 981–987 (2006).
  • Tejpar S , BertagnolliM, BosmanF et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15(4) , 390–404 (2010).
  • Simon R . Development and validation of biomarker classifiers for treatment selection. J. Stat. Plan. Inference138(2) , 308–320 (2008).
  • Amado RG , WolfM, PeetersM et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10) , 1626–1634 (2008).
  • Di Fiore F , BlanchardF, CharbonnierF et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 96(8) , 1166–1169 (2007).
  • Lievre A , BachetJB, Le Corre D et al.KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res.66(8) , 3992–3995 (2006).
  • Boland CR , GoelA. Microsatellite instability in colorectal cancer. Gastroenterology138(6) , 2073–2087.e3 (2010).
  • Des Guetz G , SchischmanoffO, NicolasP, PerretGY, MorereJF, UzzanB. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer45(10) , 1890–1896 (2009).
  • Bertagnolli MM , NiedzwieckiD, ComptonCC et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol. 27(11) , 1814–1821 (2009).
  • Fallik D , BorriniF, BoigeV et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 63(18) , 5738–5744 (2003).
  • Popat S , HubnerR, HoulstonRS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol.23(3) , 609–618 (2005).
  • Ogino S , MeyerhardtJA, KawasakiT et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 450(5) , 529–537 (2007).
  • Shen L , CatalanoPJ, BensonAB 3rd, O‘Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res.13(20) , 6093–6098 (2007).
  • Jover R , NguyenTP, Perez-CarbonellL et al. 5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140(4) , 1174–1181 (2011).
  • Esteller M , HermanJG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene23(1) , 1–8 (2004).
  • Jacinto FV , EstellerM. MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair (Amst.)6(8) , 1155–1160 (2007).
  • Agrelo R , ChengWH, SetienF et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl Acad. Sci. USA 103(23) , 8822–8827 (2006).
  • Kawasaki T , OhnishiM, SuemotoY et al. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod. Pathol.21(2) , 150–158 (2008).
  • Laird PW . The power and the promise of DNA methylation markers. Nat. Rev. Cancer3(4) , 253–266 (2003).
  • Shivapurkar N , Gazdar a F. DNA methylation based biomarkers in non-invasive cancer screening. Curr. Mol. Med.10(2) , 123–132 (2010).
  • Esteller M , Sanchez-CespedesM, RosellR, SidranskyD, BaylinSB, HermanJG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res.59(1) , 67–70 (1999).
  • Bailey VJ , EaswaranH, ZhangY et al. MS-qFRET: a quantum dot-based method for analysis of DNA methylation. Genome Res. 19(8) , 1455–1461 (2009).
  • Rifai N , GilletteMA, CarrSA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol.24(8) , 971–983 (2006).
  • Jeddeloh JA , GreallyJM, RandoOJ. Reduced-representation methylation mapping. Genome Biol.9(8) , 231 (2008).
  • Oda M , GlassJL, ThompsonRF et al. High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res. 37(12) , 3829–3839 (2009).
  • Kibriya MG , RazaM, JasmineF et al. A genome-wide DNA methylation study in colorectal carcinoma. BMC Med. Genomics 4 , 50 (2011).
  • Herman JG , GraffJR, MyohanenS, NelkinBD, BaylinSB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA93(18) , 9821–9826 (1996).
  • Eads CA , DanenbergKD, KawakamiK et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28(8) , E32 (2000).
  • Tost J , GutIG. DNA methylation analysis by pyrosequencing. Nat. Protoc.2(9) , 2265–2275 (2007).
  • Gonzalgo ML , LiangG. Methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) for quantitative measurement of DNA methylation. Nat. Protoc.2(8) , 1931–1936 (2007).
  • Brena RM , AuerH, KornackerK, PlassC. Quantification of DNA methylation in electrofluidics chips (Bio-COBRA). Nat. Protoc.1(1) , 52–58 (2006).
  • Ehrich M , NelsonMR, StanssensP et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc. Natl Acad. Sci. USA 102(44) , 15785–15790 (2005).
  • Van Vlodrop IJ , NiessenHE, DerksS et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin. Cancer Res. 17(13) , 4225–4231 (2011).
  • Mischak H , AllmaierG, ApweilerR et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med. 2(46) , 46ps42 (2010).
  • Dancey JE , DobbinKK, GroshenS et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 16(6) , 1745–1755 (2010).
  • Williams SA , SlavinDE, WagnerJA, WebsterCJ. A cost–effectiveness approach to the qualification and acceptance of biomarkers. Nat. Rev. Drug Discov.5(11) , 897–902 (2006).
  • Sawyers CL . The cancer biomarker problem. Nature452(7187) , 548–552 (2008).
  • Diamandis EP . Cancer biomarkers: can we turn recent failures into success? J. Natl Cancer Inst.102(19) , 1462–1467 (2010).
  • Luo YX , ChenDK, SongSX, WangL, WangJP. Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: a meta-analysis. Int. J. Clin. Pract.65(12) , 1313–1320 (2011).
  • Hopewell S , LoudonK, ClarkeMJ, Oxman a D, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst. Rev.1 , MR000006 (2009).
  • Ioannidis JP , TrikalinosTA. An exploratory test for an excess of significant findings. Clin. Trials4(3) , 245–253 (2007).
  • Kyzas PA , LoizouKT, IoannidisJP. Selective reporting biases in cancer prognostic factor studies. J. Natl Cancer Inst.97(14) , 1043–1055 (2005).
  • Debauve G , CapouillezA, BelayewA, SaussezS. The helicase-like transcription factor and its implication in cancer progression. Cell. Mol. Life Sci.65(4) , 591–604 (2008).
  • Mccart a E , VickaryousNK, SilverA. Apc mice: models, modifiers and mutants. Pathol. Res. Pract.204(7) , 479–490 (2008).
  • Mohammad HP , ZhangW, PrevasHS et al. Loss of a single Hic1 allele accelerates polyp formation in Apc(Delta716) mice. Oncogene 30(23) , 2659–2669 (2011).
  • Wales MM , BielMA, El Deiry W et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat. Med.1(6) , 570–577 (1995).
  • McShane LM , AltmanDG, SauerbreiW, TaubeSE, GionM, ClarkGM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Oncol.2(8) , 416–422 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.